These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 25779001)

  • 1. Crystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity.
    Lorenz S; Deng P; Hantschel O; Superti-Furga G; Kuriyan J
    Biochem J; 2015 Jun; 468(2):283-91. PubMed ID: 25779001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
    Tokarski JS; Newitt JA; Chang CY; Cheng JD; Wittekind M; Kiefer SE; Kish K; Lee FY; Borzillerri R; Lombardo LJ; Xie D; Zhang Y; Klei HE
    Cancer Res; 2006 Jun; 66(11):5790-7. PubMed ID: 16740718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
    Young MA; Shah NP; Chao LH; Seeliger M; Milanov ZV; Biggs WH; Treiber DK; Patel HK; Zarrinkar PP; Lockhart DJ; Sawyers CL; Kuriyan J
    Cancer Res; 2006 Jan; 66(2):1007-14. PubMed ID: 16424036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for the autoinhibition of c-Abl tyrosine kinase.
    Nagar B; Hantschel O; Young MA; Scheffzek K; Veach D; Bornmann W; Clarkson B; Superti-Furga G; Kuriyan J
    Cell; 2003 Mar; 112(6):859-71. PubMed ID: 12654251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that SH2 domains promote processive phosphorylation by protein-tyrosine kinases.
    Mayer BJ; Hirai H; Sakai R
    Curr Biol; 1995 Mar; 5(3):296-305. PubMed ID: 7780740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular basis of Abelson kinase regulation by its αI-helix.
    Paladini J; Maier A; Habazettl JM; Hertel I; Sonti R; Grzesiek S
    Elife; 2024 Apr; 12():. PubMed ID: 38588001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A myristoyl/phosphotyrosine switch regulates c-Abl.
    Hantschel O; Nagar B; Guettler S; Kretzschmar J; Dorey K; Kuriyan J; Superti-Furga G
    Cell; 2003 Mar; 112(6):845-57. PubMed ID: 12654250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors.
    Skora L; Mestan J; Fabbro D; Jahnke W; Grzesiek S
    Proc Natl Acad Sci U S A; 2013 Nov; 110(47):E4437-45. PubMed ID: 24191057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. Substrate specificity, authphosphorylation, and interaction with Hck.
    Yokoyama N; Miller WT
    J Biol Chem; 2003 Nov; 278(48):47713-23. PubMed ID: 14506255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two amino acid residues confer different binding affinities of Abelson family kinase SRC homology 2 domains for phosphorylated cortactin.
    Gifford SM; Liu W; Mader CC; Halo TL; Machida K; Boggon TJ; Koleske AJ
    J Biol Chem; 2014 Jul; 289(28):19704-13. PubMed ID: 24891505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571).
    Nagar B
    J Nutr; 2007 Jun; 137(6 Suppl 1):1518S-1523S; discussion 1548S. PubMed ID: 17513418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Src homology 2 domain as a specificity determinant in the c-Abl-mediated tyrosine phosphorylation of the RNA polymerase II carboxyl-terminal repeated domain.
    Duyster J; Baskaran R; Wang JY
    Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1555-9. PubMed ID: 7533294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
    Azam M; Nardi V; Shakespeare WC; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Sliz P; Veach DR; Bornmann WG; Clarkson B; Dalgarno DC; Sawyer TK; Daley GQ
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9244-9. PubMed ID: 16754879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.
    Grebien F; Hantschel O; Wojcik J; Kaupe I; Kovacic B; Wyrzucki AM; Gish GD; Cerny-Reiterer S; Koide A; Beug H; Pawson T; Valent P; Koide S; Superti-Furga G
    Cell; 2011 Oct; 147(2):306-19. PubMed ID: 22000011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming kinase resistance in chronic myeloid leukemia.
    Lee F; Fandi A; Voi M
    Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
    Seeliger MA; Ranjitkar P; Kasap C; Shan Y; Shaw DE; Shah NP; Kuriyan J; Maly DJ
    Cancer Res; 2009 Mar; 69(6):2384-92. PubMed ID: 19276351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.
    Nagar B; Hantschel O; Seeliger M; Davies JM; Weis WI; Superti-Furga G; Kuriyan J
    Mol Cell; 2006 Mar; 21(6):787-98. PubMed ID: 16543148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
    Sherbenou DW; Hantschel O; Kaupe I; Willis S; Bumm T; Turaga LP; Lange T; Dao KH; Press RD; Druker BJ; Superti-Furga G; Deininger MW
    Blood; 2010 Oct; 116(17):3278-85. PubMed ID: 20519627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.
    Fabbro D; Manley PW; Jahnke W; Liebetanz J; Szyttenholm A; Fendrich G; Strauss A; Zhang J; Gray NS; Adrian F; Warmuth M; Pelle X; Grotzfeld R; Berst F; Marzinzik A; Cowan-Jacob SW; Furet P; Mestan J
    Biochim Biophys Acta; 2010 Mar; 1804(3):454-62. PubMed ID: 20152788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation.
    Cowan-Jacob SW; Fendrich G; Manley PW; Jahnke W; Fabbro D; Liebetanz J; Meyer T
    Structure; 2005 Jun; 13(6):861-71. PubMed ID: 15939018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.